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ABSTRACT
Introduction: Despite important advances in
psychological and pharmacological treatments of
persistent depressive disorders in the past decades,
their responses remain typically slow and poor, and
differential responses among different modalities of
treatments or their combinations are not well
understood. Cognitive-Behavioural Analysis System of
Psychotherapy (CBASP) is the only psychotherapy that
has been specifically designed for chronic depression
and has been examined in an increasing number of
trials against medications, alone or in combination.
When several treatment alternatives are available for a
certain condition, network meta-analysis (NMA)
provides a powerful tool to examine their relative
efficacy by combining all direct and indirect
comparisons. Individual participant data (IPD) meta-
analysis enables exploration of impacts of individual
characteristics that lead to a differentiated approach
matching treatments to specific subgroups of patients.
Methods and analysis: We will search for all
randomised controlled trials that compared CBASP,
pharmacotherapy or their combination, in the treatment
of patients with persistent depressive disorder, in
Cochrane CENTRAL, PUBMED, SCOPUS and PsycINFO,
supplemented by personal contacts. Individual
participant data will be sought from the principal
investigators of all the identified trials. Our primary
outcomes are depression severity as measured on a
continuous observer-rated scale for depression, and
dropouts for any reason as a proxy measure of overall
treatment acceptability. We will conduct a one-step
IPD-NMA to compare CBASP, medications and their
combinations, and also carry out a meta-regression to
identify their prognostic factors and effect moderators.
The model will be fitted in OpenBUGS, using vague
priors for all location parameters. For the heterogeneity
we will use a half-normal prior on the SD.
Ethics and dissemination: This study requires no
ethical approval. We will publish the findings in a peer-
reviewed journal. The study results will contribute to
more finely differentiated therapeutics for patients
suffering from this chronically disabling disorder.
Trial registration number: CRD42016035886.
Strengths and limitations of this study
▪ This is the first systematic review and individual
participant data network meta-analysis (IPD-NMA)
comparing Cognitive-Behavioural Analysis System
of Psychotherapy (CBASP), the only psychotherapy
specifically developed to treat chronic depression,
pharmacotherapy and their combination, for per-
sistent depressive disorder.
▪ The network meta-analysis enables examination
of relative efficacy of these alternative treatments
with maximum statistical power by combining all
direct and indirect comparisons.
▪ The individual participant data meta-analysis
enables exploration of individual characteristics
as prognostic factors and effect moderators of
these alternative treatments.
▪ The study will contribute to differential therapeu-
tics that match treatments to specific subgroups
of patients and thereby maximise the overall
response rates among patients with persistent
depressive disorders.
▪ The IPD-NMA will not be able to examine vari-
ables that have not been measured in the original
studies.
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INTRODUCTION
Chronic depression has an estimated lifetime prevalence
from 3% to 6%1 2 and subsumes several clinical subtypes
including chronic major depression, recurrent major
depression with incomplete inter-episode recovery and
chronic minor depression (dysthymia). When examined
among themselves, few clinical or psychosocial differ-
ences emerged between the subtypes,3 4 and they are
now categorised together as persistent depressive dis-
order in Diagnostic and Statistical Manual Fifth Edition
(DSM-5). When compared with acute forms of depres-
sion, chronic depression is characterised by greater
comorbidity, greater social dysfunction, impaired phys-
ical health and more frequent suicide attempts and
hospitalisations.5
Despite the prominent personal and societal burden
of persistent depressive disorder, it is often under-
recognised and undertreated.6 Important advances in
psychological and pharmacological treatments have
been made in the past decades but, on average, the
responses to these treatments remain typically slow and
poor.7 Differential responses among different modalities
of treatments or their combinations remain poorly
understood, and different systematic reviews including a
network meta-analysis conclude with different recom-
mendations.8–11
This confusion may be partly due to lumping different
forms of psychotherapies into one class. In this study, we
will therefore focus on the one psychotherapy that has
been speciﬁcally designed for chronic depression, the
Cognitive-Behavioural Analysis System of Psychotherapy
(CBASP).12 It is a highly structured psychotherapy inte-
grating behavioural, cognitive and mainly interpersonal
treatment strategies. Its main therapy target is learning
to recognise the consequences of one’s own behaviour
on other persons, to develop social problem-solving
skills and to generate authentic empathy. It has been
examined against medications, alone or in combination
and against other psychotherapies, in an increasing
number of trials.
The confusion may also be partly due to failure to
account for the impact of important patient character-
istics that might modify treatment effect. Increasing
attention has been given to personalised medicine13
and, more recently, precision medicine.14 This is rele-
vant when several alternative treatments are available
and the differences in their effectiveness are, on
average, small; in such cases, a more differentiated
approach that matches treatments to speciﬁc subgroups
of patients might increase the overall response rate.15 16
Albeit a catchy phrase, ‘personalised medicine’ is prob-
ably a misnomer because medicine can never be perso-
nalised in the sense of recommending a particular
treatment to a particular individual, but can only specify
ever ﬁner smaller groups of individuals for whom one of
the many alternative treatments is expected to be more
effective than the others. We therefore prefer to use the
term ‘differential therapeutics’ to refer to this approach.
From this perspective, heterogeneity in treatment effects
is a boon. Factors that have an impact on the relative
treatment effect thus causing heterogeneity are called
effect moderators or effect modiﬁers. Methods are
rapidly developing to enable discovery of prognostic
factors (variables that predict overall response regardless
of the treatments) and effect modiﬁers (variables that
predict differential response to alternative treat-
ments).17–20 One promising approach is to apply
meta-regression to the network meta-analysis of individ-
ual participant data (IPD-NMA), which would enable
more powerful examination of the inﬂuence of both
group-level and individual-level characteristics on the
outcomes in the comparison of three or more alterna-
tive treatments.21
This study therefore aims to conduct an IPD-NMA of
CBASP, pharmacotherapy and their combination, to
identify their prognostic factors and effect moderators,
and to propose differential therapeutics in the treatment
of chronic depression.
METHODS
Criteria for considering studies for this review
We will search for all randomised controlled trials that
compared any two of CBASP, pharmacotherapy, or their
combination, in the treatment of patients with chronic
depression. No language limitation will be employed.
Participants
Participants will include men or women, aged 18 years
or older, who suffer from chronic depression. Chronic
depression includes persistent depressive disorder
(DSM-5), dysthymic disorder, or chronic major depres-
sion or recurrent major depression, with incomplete
interepisode recovery (DSM-4), or any corresponding
conditions according to standard operationalised diag-
nostic criteria.
A concurrent secondary diagnosis of another psychi-
atric disorder will not be considered as an exclusion cri-
terion, but studies in which all participants have a
concurrent primary diagnosis of another mental dis-
order will be excluded. Patients with a serious concomi-
tant medical illness, including cognitive impairment, will
be excluded, nor will we include studies where all parti-
cipants suffer from a primary medical condition.
Interventions
Participants must be allocated to one, in comparison
with another, of the following three treatments:
1. CBASP;
2. Antidepressant pharmacotherapy, which could
include any of the antidepressive agents licensed for
the treatment of major depression in the country
where the trial was conducted;22
3. Their combination.
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Search methods for identification of the studies
We will ﬁrst conduct an electronic search of Cochrane
CENTRAL, PUBMED, SCOPUS and PsycINFO, with the
keywords: CBASP or ‘Cognitive-Behavioral Analysis
System of Psychotherapy’ and Depressive disorder.
CBASP is a relatively new psychotherapy, speciﬁcally
developed for chronic depression, by James P
McCullough Jr, PhD, and the training programme has
been supervised by its developer since the early days
(http://www.cbasp.org). We will therefore conduct a
supplementary search for any additional relevant trials
through personal contact with Professor McCullough.
The list of the identiﬁed trials will then be sent out to
each study’s principal investigators to ask for further pos-
sibly relevant trials.
Data collection and management
Individual participant data including the dependent as
well as independent variables as speciﬁed below will be
sought from the principal investigators of all the identi-
ﬁed trials. Since the same or similar constructs may be
measured with different scales in each of the included
studies and different reports from the same study will be
reporting on different aspects of the conducted study,
we will also obtain their study protocols and the adminis-
tered rating scales.
The veracity of the obtained data will be cross-
examined by calculating the summary statistics
(numbers and percentages, or means and SDs) of the
baseline demographic as well as clinical variables, and
comparing them against the published reports.
Measures
Dependent variables
Our primary outcomes will be:
1. Depression severity as measured on a continuous
observer-rated scale for depression. Where different
scales such as Montgomery-Asberg Depression Rating
Scale (MADRS) or different versions of Hamilton
Rating Scale for Depression (HAM-D) are reported,
we will attempt to transform them into the 24-item
HAM-D, using the conversion table based on the
item response theory23 (http://www.ids-qids.org/
idsqids.pdf). When repeated measures are available,
we will incorporate them into the analyses.
2. Dropouts for any reason, as a proxy measure of
overall treatment acceptability.
As secondary outcomes we will use:
1. Treatment response, deﬁned as 50% or greater
reduction from baseline to study end point in the
study’s primary observer-rated depression scale
2. Remission, deﬁned as scoring below the following
validated thresholds at end point: 7 or less on
17-item HAM-D24 or 10 or less on MADRS.25
3. Depression severity as measured on a continuous self-
rating scale for depression, such as Beck Depression
Inventory (BDI) or Inventory of Depressive
Symptomatology, Self-Report. Different scales will be
converted into BDI using the conversion table of self-
rating depression scales26 (http://www.ids-qids.org/
idsqids.pdf).
4. Social functioning, as measured by any validated
measure for global social functions such as Global
Assessment of Functioning27 or Social Adjustment
Scale-Self Report.28
Independent variables
The literature suggests many candidates for effect pre-
dictors (variables associated with response regardless of
the treatment) and for effect modiﬁers (variables asso-
ciated with differential response depending on the treat-
ment) in the treatment of depression.29 We have listed
the possible candidate variables for effect predictors and
effect modiﬁers based on the literature in the following.
However, we will select the limited number of variables
to be entered into our analyses when they are particu-
larly pertinent in the differential treatment of chronic
depression in the context of psychological and pharma-
cological treatments. The variables will ﬁrst be limited
by their availability in the included original studies, but
when several variables that measure similar things are
available, the research team will discuss those we believe
are the most important predictors and those that should
be included in the model. We will also examine this
limited set of variables in the meta-regression for the
primary outcomes only.
Demographics
1. Age30
Life and social history
2. Childhood maltreatment31
3. Education32
4. Employment16 33
5. Marital status15 16 33
6. Recent life events and difﬁculties16 33
7. Social adjustment/function34
History of present illness
8. Age at onset35
9. Chronicity30
10. Number of previous episodes32 36
11. Prior treatments with antidepressants16
12. Prior treatments with psychotherapies
Present illness: symptomatology
13. Subtype of chronic depression (chronic major
depression, recurrent major depression with incom-
plete interepisode recovery, dysthymia)
14. Baseline severity37–39
15. Baseline psychomotor symptoms34 40
16. Baseline anxiety symptoms40 41
17. Baseline somatic anxiety34
18. Comorbid personality disorder16
19. Comorbid substance use/abuse40
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Therapeutic process
20. Patient preference42 43
21. Therapeutic alliance44 45
22. Early response46
23. Co-prescriptions other than antidepressants
Assessment of risk of bias
We will assess risk of bias in the included studies, using
the tool described in the Cochrane Collaboration
Handbook as a reference guide.47 The assessment will
be carried out by two independent raters. If the raters
disagree, the ﬁnal rating will be made by consensus with
the involvement (if necessary) of another member of
the review group. We will evaluate the risk of bias in the
following domains: generation of allocation sequence,
allocation concealment, blinding of study personnel and
participants, blinding of outcome assessor, attrition,
selective outcome reporting and other domains includ-
ing sponsorship bias.
Where inadequate details of allocation concealment
and other characteristics of trials are provided, the trial
authors will be contacted in order to obtain further
information. We will not include studies where sequence
generation was at high risk of bias and where allocation
was clearly not concealed.
Publication bias
To examine the association between small study effects
and the potential of publication bias, we will employ
contour-enhanced funnel plots for pairwise
meta-analyses if more than 10 studies per treatment
comparison are available,48 and comparison-adjusted
funnel plots for network meta-analyses.49 If evidence of
publication bias is found, we will incorporate this in the
interpretation of results.
Analyses
We will synthesise data using a one-step IPD
meta-analysis model assuming independent interaction
between treatment effects and covariates, as described
by Donegan et al50 (model 2). We will ‘borrow strength’
across the multiple time points by assuming that the
observations from each patient follow a multivariate
normal distribution, thus accounting for the correlation
between the observations. Then, for study j comparing
treatments X and Y, for the observations at the study’s
end point we will assume that:
mijX ¼ uj þ ajxij; if patient i received treatment X
mijY ¼ uj þ ajxij þ ðbDX  bDYÞðxij  xÞ þ djYX þ mDX
 mDY ; if patient i received Y
where X is the (arbitrarily chosen) reference treatment
for study j, dj N(0,τ2), τ2 is the heterogeneity
(common for all comparisons), xij is a covariate, and the
coefﬁcients β measure the interaction between the rela-
tive treatment effects and the covariate values. The
coefﬁcients αj measure the impact of the covariate on
the end point outcome that is irrespective of the treat-
ment being taken. The model described above pertains
to both continuous and dichotomous outcomes. The
latter will be assumed to follow a Bernoulli distribution,
where mijk (k=X,Y) will correspond to log-odds.
We will opt for IPD data from all included studies;
however, if there are studies for which only aggregated
data are available, we will include those as described in
Donegan et al by distinguishing within-trial and between-
trials interactions (model 5). If a trial is identiﬁed that
compares all three interventions, we will substitute the
random-effects distribution of δj for its bivariate
distribution.
The model will be ﬁtted in OpenBUGS, using vague
priors for all location parameters (effect sizes and
regression coefﬁcients). For the heterogeneity, we will
use a half-normal prior on the SD. We will use the select
variables from the above list as regressors.
Missing data
We will impute missing data in OpenBUGS, assuming a
missing at random (MAR) missingness mechanism.51 In
order to test robustness of this assumption, we will run a
sensitivity analysis in which we will estimate effect sizes,
assuming that the missing data are not missing at
random, and we will employ expert opinion about vari-
ables associated with informative missing.
Estimation of heterogeneity and inconsistency
We expect that heterogeneity and inconsistency intro-
duced by variability in patient characteristics will be
accounted for by the meta-regression model. Residual
heterogeneity in the data will be measured by monitor-
ing the common heterogeneity parameter τ2 and by
comparing it to its empirical distribution.52 53 Residual
inconsistency will be assessed by estimating the differ-
ence w between direct and indirect estimates in the
drug-psychotherapy-combination loop of evidence. This
will be achieved by adding w in the equation for mijP, for
studies comparing psychotherapy and combination
therapy.
DISCUSSION
We have presented the study protocol for an individual
participant data network meta-analysis of CBASP, anti-
depressant pharmacotherapy or their combination in
the treatment of persistent depressive disorder.
Possible limitations of this study protocol include the
following. First, the IPD-NMA will not be able to
examine variables that have not been measured in the
original studies. We therefore do not yet know if we will
be able to examine all or most of the variables that we
have listed in this protocol. Second, the number of
studies eligible for this IPD-NMA may be in themselves
limited and it is further possible that we may not be able
4 Furukawa TA, et al. BMJ Open 2016;6:e011769. doi:10.1136/bmjopen-2016-011769
Open Access
group.bmj.com on June 13, 2016 - Published by http://bmjopen.bmj.com/Downloaded from 
to obtain all the relevant individual participant data
from the relevant studies.
We plan to complete the study identiﬁcation and
obtain individual participant data from the relevant
studies by the end of 2016, conduct the analyses and
submit the manuscript to a peer-reviewed international
journal by mid-2017. We hope this study will elucidate
not only the differences of overall average effects of
these treatment alternatives but also factors that may
predict and moderate the treatment responses of these
treatment alternatives, and will eventually lead to mater-
ial advancement in the ﬁeld of precision medicine, by
enabling more differentiated therapeutics for patients
suffering from this chronically disabling disorder.
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